Trial NCT01243762

View at ClinicalTrials.gov 
Org. Study IDs: 0646-027

Last trial update was posted on 2018-08-16

MeSH Interventions

3-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid

MeSH Conditions

Neoplasms

Other Conditions

Neoplasms Malignant

Stopping Reasons

The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.

Limitations And Caveats

The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.

Result Publications


Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID